BCAX
Bicara Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.89
−8.63%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -66.2%
- EBIT
- -66.8%
- EPS
- -64.9%
- Free cash flow
- -33.9%
- Operating cash flow
- -33.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -15.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- -88.9%
- Net income
- —
- EPS
- —
- Free cash flow
- -43.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026